Research programme: diabetes cell therapies - Sernova
Alternative Names: Cell Pouch™ - diabetes cell therapy; Sertolin™ - diabetes cell therapyLatest Information Update: 13 Sep 2024
At a glance
- Originator JDRF; Sertoli Technologies
- Developer Sernova Corp
- Class Antihyperglycaemics; Cell therapies
- Mechanism of Action Immunomodulators; Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus